Overexpression of mutant EGFR protein indicates a better survival benefit from EGFR-TKI therapy in non-small cell lung cancer

BACKGROUND: Epidermal growth factor receptor (EGFR) is a novel target for therapy in a subset of non-small cell lung cancer (NSCLC). Tumors with EGFR mutations showed good response to EGFR tyrosine kinase inhibitors (TKIs). We aimed to identify the discriminating capacity of immunohistochemistry (IH...

Descripción completa

Detalles Bibliográficos
Autores principales: Ling, Yun, Yang, Xin, Li, Wenbin, Li, Zhuo, Yang, Lin, Qiu, Tian, Guo, Lei, Dong, Lin, Li, Lin, Ying, Jianming, Lin, Dongmei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5288154/
https://www.ncbi.nlm.nih.gov/pubmed/27418143
http://dx.doi.org/10.18632/oncotarget.10594

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5288154/
https://www.ncbi.nlm.nih.gov/pubmed/27418143
http://dx.doi.org/10.18632/oncotarget.10594

Ejemplares similares